The UK's Medicines and Healthcare products Regulatory Agency approved the agent together with trastuzumab and chemo based on the Phase II HER2CLIMB trial.
The MHRA relied on objective response rates in previously treated, HER2-positive patients in the DESTINY-Breast01 trial to make its decision on the drug.
NICE cited uncertainties about the cost-effectiveness of Verzenio due to higher doses and longer treatment needed for patients to benefit from the drug.